Status:

COMPLETED

Effects of Substance P Antagonists on Adrenal Secretion

Lead Sponsor:

University Hospital, Rouen

Conditions:

Healthy Volunteers

Eligibility:

MALE

18-30 years

Phase:

PHASE4

Brief Summary

Data from the literature and previous in vitro research conducted in the investigators' laboratory (INSERM U413/EA4310, University of Rouen) suggest that adrenal corticosteroid secretion might be cont...

Detailed Description

STUDY DESIGN Phase IV, proof of concept, interventional, monocentric, randomised, double blind, cross-over study: The effects of a substance P antagonist (Emend) on corticosteroid secretion will be c...

Eligibility Criteria

Inclusion

  • Male subjects;
  • Age ranging 18 - 30 years old;
  • Submitted to a social security regimen;
  • Agreeing to the study \& Informed consent form signed;
  • Body mass index (\[weight (kg)/height (m)\]²) \< 27;
  • No treatment received 6 weeks before inclusion;
  • No anomaly after: complete clinical examination, pulse and blood pressure measurement, ECG;
  • No biological abnormality after the following biological testing:
  • Hematology: white \& red blood cells \& platelets count, haemoglobin, hematocrit
  • Blood biochemistry: sodium, potassium, chloride, bicarbonate, creatinine, urea
  • Urinary biochemistry (24 h collection): cortisol, aldosterone
  • Serologies: HIV, HBV, HCV
  • No participation in a clinical trial 3 months before inclusion.

Exclusion

  • Subject not agreeing to the study or impossible to follow-up;
  • Known history of significant medical or surgical pathology, notably endocrine;
  • Renal or hepatic insufficiency;
  • Nephrotic syndrome;
  • Edematous syndrome;
  • Hypertension or postural hypotension;
  • Cardiac rhythm or conduction pathologies;
  • Cardiac insufficiency;
  • Epilepsy;
  • Significant psychiatric disorder;
  • Known history of severe allergy, hypersensitivity to aprepitant ant/or metoclopramide;
  • Hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficit;
  • Impaired lactose tolerance.

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2010

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00977223

Start Date

June 1 2009

End Date

June 1 2010

Last Update

February 16 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rouen Clinical research Centre (CIC 0204)

Rouen, Haute Normandie, France, 76031

Effects of Substance P Antagonists on Adrenal Secretion | DecenTrialz